Dechra Acquires Rompun® (xylazine injection) 100mg/ml and Butorphanol Tartrate Injection 10mg/ml from Elanco™ Animal Health

Friday, October 15, 2021

Acquisition expands Dechra’s equine portfolio into the anesthesia and analgesia category.

Dechra is pleased to announce the acquisition of Rompun® (xylazine injection) 100mg/ml and Butorphanol Tartrate Injection 10mg/ml from Elanco™ Animal Health. Rompun is a sedative that veterinarians have come to know and trust for decades. Butorphanol also compliments the Dechra portfolio with its centrally acting analgesic activity.
Mike Eldred, President of Dechra North America, stated, “These two products are cornerstone drugs in their respective categories and will serve to help us continue to build out our already highly regarded equine portfolio.”

Both Rompun and Butorphanol should be used solely by veterinarians.

About Dechra
Dechra Veterinary Products’ equine portfolio includes Osphos® (clodronate injection), Orthokine® vet irap 10 and 60, and Osteokine® (PRP). Dechra also offers Equidone® Gel (domperidone), the Vetivex® line of parenteral fluids, Phycox® EQ joint health supplements, and a comprehensive line of topical dermatologic products. The recent additions of ProVet APC™ (Autologous Platelet Concentrate) system and Zimeta® (dipyrone injection) further expand Dechra’s equine offerings.

For questions or further information, please contact Mike Eldred or Doug Hubert:

Mike Eldred, President, North American Operations, Dechra Veterinary Products, Mike.Eldred@Dechra.com

Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products, Doug.Hubert@Dechra.com